Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment

European Urology, Supplements

Volumn 8, Issue 9, 2009, Pages 738-746

  Fitzpatrick, John M ^a   Sternberg, Cora N ^b   Saad, Fred ^c   Extermann, Martine ^d   Caffo, Orazio ^e   Halabi, Susan ^f   Kramer, Gero ^g   Oudard, Stéphane ^h   de Wit, Ronald ⁱ  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e SANTA CHIARA HOSPITAL   (Italy)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Advanced bladder cancer; Advanced renal cell carcinoma; Case studies; Castrate resistant prostate cancer; Docetaxel; Genitourinary cancers; Nomogram; Retreatment; Risk assessment; Senior adult patients

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ESTRAMUSTINE; EVEROLIMUS; GAMMA INTERFERON; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SORAFENIB; STRONTIUM; SUNITINIB; TEMSIROLIMUS; TESTOSTERONE; VINBLASTINE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ANEMIA; BLADDER CANCER; BLADDER CARCINOMA; BONE METASTASIS; CANCER PAIN; CANCER RELAPSE; CASTRATE RESISTANT PROSTATE CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTECTOMY; EDEMA; HEALTH STATUS; HEMATOLOGIC DISEASE; HUMAN; KIDNEY CARCINOMA; METASTASIS; MINI MENTAL STATE EXAMINATION; NAIL DISEASE; NOMOGRAM; ONCOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RETREATMENT; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT PLANNING; UROLOGY; VISCERAL METASTASIS; WEIGHT GAIN;

EID: 68949192787     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.06.001     Document Type: Review

References (54)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
5. Dawson N.A., and McLeod D.G. The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 33 (1997) 560-565
6. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
7. Oudard S., Banu E., Medioni J., et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. BJU Int 103 (2009) 1641-1646
8. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
9. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
10. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396-6403
11. SEER stat fact sheets. National Cancer Institute Surveillance Epidemiology and End Results Web page. http://seer.cancer.gov/statfacts/html/prost.html. Accessed April 30, 2009.
12. Kataja V.V., and Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 16 Suppl 1 (2005) i34-i36
13. Beer T.M., Berry W., Wersinger E.M., and Bland L.B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2 (2003) 167-172
14. Droz J, Sternberg C, Balducci L, et al. International Society of Geriatric Oncology (SIOG) prostate cancer guidelines proposal in senior adult men [abstract 253]. American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20410. Accessed April 30, 2009.
15. Begg C.B., Riedel E.R., Bach P.B., et al. Variations in morbidity after radical prostatectomy. N Engl J Med 346 (2002) 1138-1144
16. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., and Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
17. Koroukian S.M., Murray P., and Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 24 (2006) 2304-2310
18. Chen H., Cantor A., Meyer J., et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 97 (2003) 1107-1114
19. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., and Tannock A.I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14 (2008) 2763-2767
20. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 (2007) 556-563
21. Sartor AO, Petrylak DP, Witjes JA, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial [ASCO abstract 5003]. J Clin Oncol 2008;26:p250s.
22. Eymard J, Oudard S, Gravis G, et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormone-refractory prostate cancer (mHRPC) [abstract 249]. American Society of Clinical Oncology 2007 Prostate Cancer Symposium. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=46&abstractID=20375. Accessed April 30, 2009.
23. Caffo O, Sava T, Comploj E, et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol. In press. doi:10.1016/j.urolonc.2008.07.033.
24. Berthold D.R., Pond G.R., de Wit R., Eisenberger M., and Tannock I.F. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19 (2008) 1749-1753
25. Kramer G., Schwarz S., Hagg M., Havelka A.M., and Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94 (2006) 1592-1598
26. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
27. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
28. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 Suppl 1 (2000) S55-S57
29. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
30. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18 (2000) 2972-2980
31. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
32. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
33. Pantuck A.J., Zeng G., Belldegrun A.S., and Figlin R.A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9 (2003) 4641-4652
34. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
35. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
36. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
37. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
38. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
39. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
40. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
41. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
42. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
43. Loehrer Sr. P.J., Elson P., Dreicer R., et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 12 (1994) 483-488
44. Logothetis C.J., Finn L.D., Smith T., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13 (1995) 2272-2277
45. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
46. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
47. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
48. Bellmunt H, von der Masse H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study [ASCO abstract 5030]. J Clin Oncol 2007;25:p242s.
49. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671-1678
50. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18 (2000) 3247-3255
51. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
52. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
53. Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., and Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998
54. Bellmunt J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU) [ASCO abstract 5028]. J Clin Oncol 2008;26:p257s.